key: cord-0721128-9juxfxwe
authors: Giardino, Giuliana; Romano, Roberta; Coppola, Emma; Cillo, Francesca; Borzachiello, Carla; De Luca, Martina; Palamaro, Loredana; Toriell, Elisabetta; Prencipe, Rosaria; Cirillo, Emilia; Pignata, Claudio
title: SARS-CoV-2 infection in the immunodeficient host: necessary and dispensable immune pathways
date: 2021-07-15
journal: J Allergy Clin Immunol Pract
DOI: 10.1016/j.jaip.2021.06.045
sha: ef4fde908f0e1b029ad011fe57097f019e137de8
doc_id: 721128
cord_uid: 9juxfxwe

Since its outbreak in late December 2019 in Wuhan, COVID-19 pandemic has posed a therapeutic challenge for the world population, with a plenty of clinical pictures and a broad spectrum of severity of the manifestations. In spite of initial speculations on a direct role of primary or acquired immune deficiency in determining a worse disease outcome, recent studies have provided evidence that specific immune defects may either serve as an experimentum naturae entailing this risk or may not be relevant enough to impact the host defense against the virus. Taken together, these observations may help unveil pathogenetic mechanisms of the infection and suggest new therapeutic strategies. Thus, in this review we summarize current knowledge regarding the mechanisms of immune response against SARS-CoV-2 infection and clinical manifestations with a special focus on children and patients presenting with congenital or acquired immune deficiency.

COVID-19 has emerged as a novel infectious disease that spread worldwide, causing 80 nearly 4 million deaths, presenting with pulmonary symptoms and, in some cases, evolving 81 to multiorgan failure and death. 1 Since its first description, the huge variability of the clinical 82 manifestations has prompted studies aimed at identifying risk factors and predictors of worse 83 outcome. To date, older age, male sex and pre-existing comorbidities have been recognized 84 against the host immune response. 18 To evade Pattern Recognition Receptors (PRRs), 158 SARS-CoV-2 modifies and shields its replicating RNA, through the processes of guanosine-159 capping, methylation and/or other mechanisms. [19] [20] [21] Additional strategies to escape innate 160 immunity are related to the interaction between viral proteins and signaling mediators of the 161

Toll-Like receptors (TLRs)/RIG-I like receptors (RLRs) pathways, such as TANK-binding 162 kinase 1 (TBK1) and Interferon regulatory factor 3 (IRF3), which results in an inhibition of 163 signal transduction. 18 The escape from innate immunity receptors leads to an impaired 164 production of IFN-I, which has been shown to be lower in patients with severe disease. 22 165

Nevertheless, in patients with severe disease, a higher plasma concentration of 166 inflammatory cytokines, such as IL-2, IL-7, IL-6, IL-10, TNF- was found. 23 This cytokine 167 storm is caused by the massive recruitment of monocytes/macrophages and neutrophils 168 from the bloodstream to the site of infection, eliciting an excessive and poorly controlled 169 inflammatory response and tissue damage/systemic inflammation. 24, 25 Another mechanism 170 implicated in the severity of SARS-CoV-2 infection is represented by the antibody-171 dependent enhancement (ADE). ADE is due to the presence of low-affinity IgG antibodies, 172 which are unable to eliminate the virus and facilitate its entry into the cell. The antibody/S 173 protein complex binds to the Fc receptor (FcR) on monocytes/macrophages and to alveolar 174 epithelial cells favoring the entry of the virus in the cell. 3, 26, 27 This mechanism also elicits a 175 proinflammatory response. 176 177

Cytokine storm is frequent in severe COVID-19 cases and leads to the development 179 of ARDS, DIC and MOF, increasing infection-associated mortality. It is characterized by 180 unremitting high fever, lymphadenopathy, hepatosplenomegaly, hyperferritinemia, 181 hemodynamic instability, cytopenia, abnormalities of the central nervous system with a 182 J o u r n a l P r e -p r o o f frequent progression towards MOF. [28] [29] [30] [31] [32] This condition has been described in 183 haemophagocytic lymphohistiocytosis (HLH), where the mutation of genes involved in the 184 granule release hinders cytotoxic activity of NK and CD8+ T cells or in other forms of 185 congenital immune deficiencies when a failure of viral clearance occurs. 33 Under these 186 conditions, the ineffective clearance of the antigenic stimuli leads to macrophages and Th1 187 cells hyper-activation with excessive secretion of proinflammatory cytokines, in particular IL-188 1, IL-6, IL-8, IL-10, which amplify the typical cytokine storm hyperinflammatory state. 34, 35 189 Endothelial activation mediated by IL-6 and IFN- is involved in the pathogenesis of cytokine 190 storm, contributing to hemodynamic instability, capillary leak and DIC. 36 Endothelial cells are 191 stimulated to produce von Willebrand factor and Angiopoietin-II, as well as IL-6 itself, leading 192 to a hypercoagulability status. 37 193

Lymphopenia is considered a criterion of severity. In patients with severe 196 T cells and NK cells are usually low, while B cells are at the lower levels of the normal 197 range. 23, [38] [39] [40] In severe cases, significant reduction of Treg cells, causing T-cell 198 dysregulation and hyperinflammation, may be observed. 39, 40 Lymphocyte subsets express 199 an exhausted phenotype as suggested by the high level of expression of programmed death Cytokine excess, particularly IL-6, induces Fas-mediated T-cell apoptosis. 46 Severe 205 patients also have higher specific IgM and IgG titers. 17 Finally, hospitalized patients manifest 206 significantly increased levels of C Reactive Protein (CRP), D-dimer and procalcitonin, when 207 compared to patients with mild pathology. 47 208

Children have a limited role in COVID-19 pandemic. 48, 49 As of June 2021, in the 211 United States, children account for approximately 14 percent of laboratory-confirmed cases 212

reported to the Centers for Disease Control and Prevention (www.cdc.gov/covid-data-213 tracker/index.html#demographics). In the early phases of the outbreak, children were rarely 214 tested for the virus since symptoms of COVID-19 are usually less severe and most cases 215 are asymptomatic or show mild-to-moderate clinical features. 1, 6, 24, 27, 40, In September 216

and October, the case notification rate increased rapidly and so did the number of pediatric 217 cases as compared to the start of the pandemic; 78 however, percentages of pediatric cases 218 remain far below those of adults. 79 

Children have higher probability to have extra-respiratory symptoms 80 as diarrhea 220 and vomiting. The case fatality rate (CFR) for children and adolescent in Europe is less than 221 1%, thus confirming that also children may experience a severe course of disease. In a 222 metanalysis grouping more than 1000 children under five years of age, 43% were 223 asymptomatic and 7% required intensive-care-unit admission. 81 Risk factors for a worse 224 outcome in children are: age younger than 1 month, male sex, presence of lower respiratory 225 tract infection signs or symptoms at presentation and presence of a pre-existing medical 226 condition. 78 Children with viral co-infection were more likely to require Intensive Care Unit 227 (ICU) support. 78 

Children may also experience severe multisystem inflammation with clinical features 229 in common with Kawasaki disease (KD) and toxic shock syndrome (TSS). It can be 230 associated with actual or previous positivity to SARS-CoV-2. 82 This syndrome has been 231 recently named multisystem inflammatory syndrome in children (MIS-C). 83 Agammaglobulinemia (XLA) was reported, the latter having a mild disease. The authors 249 hypothesized that B lymphocytes might enhance the inflammatory response against the 250 virus through the release of IL-6, while an increased risk of relapse may be hypothesized 251 due to the absence of antibodies. 92, 93 The authors also argue in favor of an indirect 252 advantage for XLA patients provided by the lack of Bruton's tyrosine kinase (BTK). In 253 myeloid/macrophage cells, BTK is, indeed, responsible for the production of cytokines, such 254 as TNF-α and IL-6 94 and for the activation of NLRP3 inflammasome with the secretion of IL-255 1β. 95 In an off-label clinical study on 19 hospitalized patients with COVID-19 and severe 256 hypoxia, who received a selective BTK inhibitor, Acalabrutinib, normalization of laboratory 257 markers and improved oxygenation was observed after the treatment. 96 

A retrospective study conducted on a cohort of 94 patients, median age 25-34 years, 259

with SARS-CoV-2 infection and IEI including antibody deficiency, innate immune defect, 260 J o u r n a l P r e -p r o o f combined immunodeficiency, phagocyte defect, immune dysregulation syndrome, auto-261 inflammatory disorders and bone marrow failure showed that more than half of the subjects 262 were managed as inpatients while a mild clinical picture was observed in more than 30% of 263 patients. Asymptomatic or mild clinical picture was observed in patients affected with XLA 264 or ZAP70, PGM3, and STAT3. Similar to the general population, a male predominance was 265 noted, not only for infection incidence but also for ICU admission. Also the association 266 between pre-existing risk factors (e.g. kidney, lung or heart disease, diabetes, obesity) and 267

severe COVID-19 mirrored the general population. 1, 23 However, the authors underlined the 268 younger age of severely affected patients and an increased ICU admission rate in IEI. 97 In 269 a recent study on patients affected with IEI or symptomatic secondary immune deficiency, In this scenario, the identification in 3 patients with autoimmune polyendocrinopathy 282 syndrome type I who suffered from life-threatening COVID-19 pneumonia of anti-IFN-I 283 autoantibodies paved the way to investigating the impact of these neutralizing 284 autoantibodies. 102 Bastard and colleagues compared anti-IFN-I autoantibodies among 285 patients, with either critical or asymptomatic/mild disease and healthy controls. In the latter 286 group, only 4% were positive, while patients with asymptomatic or mild clinical picture were 287 negative. In contrast, high titers of neutralizing anti-IFN-I autoantibodies were found in more 288 than 10% of patients with severe disease, especially men (12.5% vs 2.6% of women), 289 partially contributing to explain the sex bias. One of the women with life-threatening COVID-290 19 and autoantibodies had X chromosome-linked incontinentia pigmenti. 103 The study of patients with acquired immunodeficiency further confirmed the 299 hypothesis that an immunosuppressive status alone may not be responsible for a worse 300 prognosis. In a systematic review on the impact of immunosuppressive condition on SARS-301

CoV-2 infection outcome, patients affected with leukemia and patients who had undergone 302 liver transplantation had an overall favorable disease course, as compared to the general 303 population. 105 are not eligible for the treatment with remdesivir or when remdesivir is not available, include 353 lopinavir/ritonavir, a FDA approved protease inhibitor indicated for treatment of HIV. 119, 120 354 However, recent reports claimed for no benefits of this agent in pediatric and adult 355

A preventive anticoagulant therapy with subcutaneous enoxaparin may be 357 considered for patients in whom a higher incidence of thrombotic complications has been 358 observed. 121 Since the beginning of the pandemic, chloroquine and hydroxychloroquine 359 have emerged as potential drugs for their supposed antiviral and immunomodulatory effects 360

and their use was initially approved by FDA. 122, 123 Recently, due to safety concerns complications. 127 On the other hand, treatment stopping is not needed in patients with other 375 underlying conditions. Other immunomodulatory agents are being evaluated for their 376 potential roles in the context of hyperinflammatory syndrome due to cytokine release 377 including convalescent plasma, intravenous immunoglobulins, anakinra, tocilizumab and 378 JAK inhibitors. Anakinra is a non-glycosylated human IL-1 receptor antagonist, acting 379 against proinflammatory cytokines IL-1α and -1β that reduces both need for intensive care 380 and mortality among patients with COVID-19 severe forms. 128 Although preclinical data and 381 observational studies support treatment with tocilizumab, no randomized controlled trial has 382 proved, so far, the effectiveness or the safety of this biologic drug in COVID-19. 129 In keeping 383 with available, yet inconclusive data, NIH guidelines recommends against its use. Psoriatic arthritis (21) Rheumatoid arthritis (20) Ulcerative colitis (17) Crohn's disease (20) Other (9) Required hospitalization (14) Admission to the Intensive care (1) Invasive mechanical ventilation (1) Death (1) The clinical course after SARS-CoV2 infection was not different compared to general population 111 Prednisone (12) Immunosoppressive agent (7) SLE (17) Required hospitalization (14) Admission to the Intensive care (7) Invasive mechanical ventilation (5) Death (4) Prednisolone (189) DMARDs ( 

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Origin and evolution of pathogenic coronaviruses

Clinical Characteristics of 34 Children with Coronavirus Disease-2019 in the West of China: a Multiple-center Case Series

Probable Pangolin Origin of SARS-CoV-2 Associated with the COVID-19 Outbreak

A Novel Coronavirus from Patients with Pneumonia in China

SARS-CoV-2 Infection in Children

The human coronavirus HCoV-229E S-protein structure and receptor binding

Coronavirus membrane fusion mechanism offers a potential target for antiviral development

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes

Nafamostat Mesylate Blocks Activation of SARS-CoV-2: New Treatment Option for COVID-19

Coronavirus-19 (SARS-CoV-2) induces acute severe lung inflammation via IL-1 causing cytokine storm in COVID-19: a promising inhibitory strategy

The Greek study in the effects of colchicine in COvid-19 complications prevention (GRECCO-19 study): Rationale and study design

Influenza virus-specific CD4+ and CD8+ T cell-mediated immunity induced by infection and vaccination

Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections

Immunemediated approaches against COVID-19

Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19

A SARS-CoV-2-Human Protein-Protein Interaction Map Reveals Drug Targets and Potential Drug-Repurposing

In vitro reconstitution of SARS-coronavirus mRNA cap methylation

Functional screen reveals SARS coronavirus nonstructural protein nsp14 as a novel cap N7 methyltransferase

Multiple enzymatic activities associated with severe acute respiratory syndrome coronavirus helicase

Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

The different clinical characteristics of corona virus disease cases between children and their families in China -the character of children with COVID-19

COVID-19: consider cytokine storm syndromes and immunosuppression

Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection

COVID-19 Transmission Within a Family Cluster by Presymptomatic Carriers in China

Review: Cytokine Storm Syndrome: Looking Toward the Precision Medicine Era

Management of cytokine release syndrome related to CAR-T cell therapy

Cytokine storm and sepsis disease pathogenesis

Cytokine release syndrome

Pathogenesis of Hemophagocytic Lymphohistiocytosis

Macrophage activation syndrome in adults: recent advances in pathophysiology, diagnosis and treatment

Macrophage activation syndrome: characteristic findings on liver biopsy illustrating the key role of activated, IFN-gamma-producing lymphocytes and IL-6-and TNF-alpha-producing macrophages

Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy

Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells

Pathological findings of COVID-19 associated with acute respiratory distress syndrome

Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China

Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study

Use of Convalescent Plasma Therapy in Two COVID-19 Patients with Acute Respiratory Distress Syndrome in Korea

Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients

Platelet-to-lymphocyte ratio is associated with prognosis in patients with coronavirus disease-19

The trinity of COVID-19: immunity, inflammation and intervention

CD147-spike protein is a novel route for SARS-CoV-2 infection to host cells

The Novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Directly Decimates Human Spleens and Lymph Nodes

Predictive factors for pneumonia development and progression to respiratory failure in MERS-CoV infected patients

Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention

COVID-19 in children: analysis of the first pandemic peak in England

Prolonged viral shedding in feces of pediatric patients with coronavirus disease 2019

Clinical analysis of 31 cases of 2019 novel coronavirus infection in children from six provinces (autonomous region) of northern China

Coronaviruses and Immunosuppressed Patients: The Facts During the Third Epidemic

Clinical and CT features in pediatric patients with COVID-19 infection: Different points from adults

Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding

Clinical and CT imaging features of the COVID-19 pneumonia: Focus on pregnant women and children

Chest computed tomography in children with COVID-19 respiratory infection

Clinical features of pediatric patients with COVID-19: a report of two family cluster cases

First Pediatric Case of Coronavirus Disease 2019 in Korea

Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury

A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster

A Well Infant With Coronavirus Disease 2019 With High Viral Load

Novel Coronavirus Infection in Hospitalized Infants Under 1 Year of Age in China

Diagnosis and treatment of 2019 novel coronavirus infection in children: a pressing issue

Three children who recovered from novel coronavirus 2019 pneumonia

Detection of Novel Coronavirus by RT-PCR in Stool Specimen from Asymptomatic Child

Insight into COVID-2019 for pediatricians

Asymptomatic cases in a family cluster with SARS-CoV-2 infection

The digestive system is a potential route of 2019-nCov infection: a bioinformatics analysis based on single-cell transcriptomes

Novel coronavirus infection in children outside of Wuhan, China

Coronavirus Disease 2019 in Children -United States

Children with Covid-19 in Pediatric Emergency Departments in Italy

COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study

Coronavirus Disease

Coronavirus Infections in Children Including COVID-19: An Overview of the Epidemiology, Clinical Features, Diagnosis, Treatment and Prevention Options in Children

Epidemiology of COVID-19 infection in young children under five years: A systematic review and meta-analysis

COVID-19 and Kawasaki Disease: Finding the Signal in the Noise

Hyperinflammatory shock in children during COVID-19 pandemic

Acute Heart Failure in Multisystem Inflammatory Syndrome in Children in the Context of Global SARS-CoV-2 Pandemic

Kawasaki-like multisystem inflammatory syndrome in children during the covid-19 pandemic in Paris, France: prospective observational study

An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study

Clinical Characteristics of 58 Children With a Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2

Multisystem Inflammatory Syndrome in Children in New York State

Multisystem Inflammatory Syndrome in U.S. Children and Adolescents

Pediatric Coronavirus Disease-2019-Associated Multisystem Inflammatory Syndrome

Kawasaki-like disease: emerging complication during the COVID-19 pandemic

A possible role for B cells in COVID-19? Lesson from patients with agammaglobulinemia

Two X-linked agammaglobulinemia patients develop pneumonia as COVID-19 manifestation but recover

Bruton's tyrosine kinase regulates TLR7/8-induced TNF transcription via nuclear factor-κB recruitment

Human NACHT, LRR, and PYD domain-containing protein 3 (NLRP3) inflammasome activity is regulated by and potentially tyrosine kinase

Inhibition of Bruton tyrosine kinase in patients with severe COVID-19

COVID-19 in patients with primary and secondary immunodeficiency: The United Kingdom experience

Minor Clinical Impact of COVID-19 Pandemic on Patients With Primary Immunodeficiency in Israel

Clinical outcome, incidence, and SARS-CoV-2 infection-fatality rates in Italian patients with inborn errors of immunity. The journal of allergy and clinical immunology

Human genetics of life-threatening influenza pneumonitis

A COVID-19 pneumonia case report of autoimmune polyendocrine syndrome type 1 in Lombardy, Italy: letter to the editor

Autoantibodies against type I IFNs in patients with life-threatening COVID-19

Immune dysregulation and multisystem inflammatory syndrome in children (MIS-C) in individuals with haploinsufficiency of SOCS1

Modeling the transmission dynamics of COVID-19 epidemic: a systematic review

How is immunosuppressive status affecting children and adults in SARS-CoV-2 infection? A systematic review

Determinants of COVID-19 disease severity in patients with cancer

Does immunosuppressive treatment entail an additional risk for children with rheumatic diseases? A survey-based study in the era of COVID-19

The conundrum of COVID-19 treatment targets: the close correlation with rheumatology. Response to: 'Management of rheumatic diseases in the time of covid-19 pandemic: perspectives of rheumatology pracitioners from India' by Gupta et al and 'Antirheumatic agents in covid-19: is IL-6 the right target

Absence of severe complications from SARS-CoV-2 infection in children with rheumatic diseases treated with biologic drugs

Covid-19 in Immune-Mediated Inflammatory Diseases -Case Series from New York

The severity of COVID-19 in children on immunosuppressive medication

Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry

Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient

A Survey for COVID-19 Among HIV/AIDS Patients in Two Districts of Wuhan

HIV and risk of COVID-19 death: a population cohort study from the Western Cape Province

Coronaviruses lacking exoribonuclease activity are susceptible to lethal mutagenesis: evidence for proofreading and potential therapeutics

Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease

A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19

Treatment of children with COVID-19: position paper of the Italian Society of Pediatric Infectious Disease

Developmental hemostasis: clinical implications from the fetus to the adolescent

COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression

New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?

Dexamethasone in Hospitalized Patients with Covid-19 -Preliminary Report

Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease

Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury

Corticosteroid Therapy for Critically Ill Patients with Middle East Respiratory Syndrome

Controlled Trial of Ebola Virus Disease Therapeutics

Efficacy of Tocilizumab in Patients Hospitalized with Covid-19

Mild SARS-CoV-2 Infection After Gene Therapy in a Child With Wiskott-Aldrich Syndrome: A Case Report

Fatal SARS-CoV-2 infection in a male patient with Good's syndrome

COVID-19 in a child with primary antibody deficiency

Severe SARS-CoV-2 disease in the context of a NF-κB2 loss-of-function pathogenic variant

Impact of SARS-CoV-2 Pandemic on Patients with Primary Immunodeficiency

Clinical course of COVID-19 among immunocompromised children: a clinical case series

COVID-19 in Autoinflammatory Diseases with Immunosuppressive Treatment

An early experience of COVID-19 disease in pediatric and young adult renal transplant recipients

Clinical outcome of SARS-CoV-2 infection in immunosuppressed children in Spain

Two Cases of SARS-CoV-2 Infection in Pediatric Oncohematologic Patients in Spain

Varying presentations of COVID-19 in young heart transplant recipients: A case series

Characterization of COVID-19 disease in pediatric oncology patients: The New York-New Jersey regional experience

Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine

A Case Series of Five People Living with HIV Hospitalized with COVID-19 in

COVID-19 in patients with HIV: clinical case series

COVID-19 in people living with human immunodeficiency virus: a case series of 33 patients

Description of COVID-19 in HIV-infected individuals: a single-centre, prospective cohort

Coronavirus 2019 and People Living With Human Immunodeficiency Virus: Outcomes for Hospitalized Patients